Clin Nucl Med 2021 Apr 30. Epub 2021 Apr 30.
From the *The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran †Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden ‡Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, Germany §Department of Oncology, Salman Farsi Hospital, Bushehr, Iran ∥Nanomab Technology Limited, Shanghai, People's Republic of China ¶Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Breast cancer is the most frequent invasive malignancy and the second major cause of cancer death in female subjects mostly due to the considerable diagnostic delay and failure of therapeutic strategies. Thus, early diagnosis and possibility to monitor response to the treatment are of utmost importance. Identification of valid biomarkers, in particular new molecular therapeutic targets, that would allow screening, early patient identification, prediction of disease aggressiveness, and monitoring response to the therapeutic regimen has been in the focus of breast cancer research during recent decades. Read More